Beyond the lab: immuno-oncology
Read this in-depth analyses and insights from leading experts in the field focusing on treatments, new technologies and engineered bacteria.
List view / Grid view
Read this in-depth analyses and insights from leading experts in the field focusing on treatments, new technologies and engineered bacteria.
In this Q&A, founder of Scheer Medical Wellness Dr Alexander Scheer shares his insights, discussing the current challenges in stem cell therapy and how these can be addressed, the advancements in delivery techniques, and stem cells’ overall potential in regenerative medicine.
A novel cellular mechanism has been uncovered with the use of CRISPR gene-tiling technology, which could advance oncologic therapies.
A novel technology can reduce tumour sizes significantly and improve treatment efficacy when used with existing immunotherapy.
For the first time, mitochondrial DNA mutations could be used with immunotherapy to increase the chances of successful treatments.
Researchers discover that blocking PD-L2 in senescent cells increases the efficacy of chemotherapy in mouse models.
In this exclusive interview, Dr Espen Basmo Ellingsen, a luminary in cancer immunology, provides insights into the anticipated breakthroughs, collaborative endeavours, and personalised strategies that promise to elevate the effectiveness and durability of immuno-oncology interventions.
AcrlC8 and AcrlC9 prevent the CRISPR-Cas3 machine from binding to its DNA target site, providing a safer way to engineer the genome.
Researchers explored the effects of loops and 3D genome organisation on gene silencing, and found that ‘cohesinopathies’ may be linked it.
Oligodendrocyte precursor cells and the synapses they form with neurons could be relevant to many disease conditions, including cancer.
Dr Daniel Kavanagh, Senior Scientific Advisor, Gene Therapies, Vaccines and Biologics at WCG, discusses how monoclonal antibodies are limited by their ability to only recognise tumour antigens expressed on the outside surface of a cell. In this article he explains how investigational genetically engineered medicinal products are leveraging T-cell receptors…
Dr Ketan Patel, Clarivate, shares his insights about the use of Real-World Data and genomic biomarker data and discusses how researchers can use these to better detect and diagnose diseases.
Disruptions in TP53 and RB1 are key influencers that cause changes in the risk of mutations across chromosomes.
Novel self-assembled amino acid-based nanoparticles, loaded with doxorubicin, could evolve cancer treatment.
Using bioinformatics analyses, HK-CREs impact on cellular processes was studied, including their potential as housekeeping tumour suppressors.